期刊文献+

肝移植术后乙型肝炎复发防治新策略

原文传递
导出
摘要 由于乙型肝炎免疫球蛋白(HBIG)联合拉米夫定(LAM)能显著降低肝移植术后乙型肝炎的复发率,因此,该治疗方案已被广泛接受,用于防治肝移植术后乙型肝炎的复发。但是,随着临床的推广使用,新的问题不断出现,如HBIG费用昂贵、使用不便,HBV基因变异导致的耐药,新型核苷类似物的合理应用,乙型肝炎复发后的治疗,重建HBV主动免疫等。在此,谈谈对上述问题的看法,与大家共同探讨。
作者 郑树森
出处 《中华传染病杂志》 CAS CSCD 北大核心 2008年第8期449-451,共3页 Chinese Journal of Infectious Diseases
  • 相关文献

参考文献6

  • 1Zheng SS,Chen YM, Liang TB, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl, 2006, 12:253-258.
  • 2Dan YY, Wai CT, Yeoh KG, et al. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a costeffectiveness analysis. Liver Transpl, 2006, 12:736 746.
  • 3Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for longterm prophylaxis of hepatitis B recurrence after liver transplantation.J Hepatol, 2001, 34: 888-894.
  • 4Neff GW, Zacharias VC, Alonzo M, et al. Conversion of liver transplant recipients with hepatitis B virus from hepatitis B immune globulin ( HBIG ) and lamivudine (LAM) to adefovir dipivoxil (ADV) and LAM. 41st Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, 2006.
  • 5Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and postliver transplantation patients with lamivudineresistant hepatitis B: final long-term results. Liver Transpl, 2007, 13: 349-360.
  • 6Lo CM, Lau GK, Chan SC, et al. Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant, 2007, 7: 434-439.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部